List view / Grid view
The era of precision medicine demands more rigorous biomarker validation methods. While ELISA has long been the gold standard, advanced technologies such as LC-MS/MS and Meso Scale Discovery (MSD) offer superior precision, sensitivity and efficiency. Here, Prasad Lakshmanan Selvaraj, Director of Technical Review at Sannova, explains that by embracing these…
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
Conventional methods for radiolabelling proteins are time consuming and difficult to automate. In this article, Jason P. Holland discusses how combining photochemistry with radiochemistry enables development of radiolabelled proteins far more quickly and easily – literally in a flash of light.
New permanent building to be completed by 15 November 2019...
The EMA Management Board have met in an extraordinary session to discuss EMA’s future premises in Amsterdam...
The EMA will relocate to Amsterdam in the Netherlands. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest...
Wayne Pines, President of Healthcare at APCO Worldwide in Washington DC and a former Associate Commissioner of the FDA believes Milan is a logical choice for the relocation of the EMA...
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
5 December 2016 | By Niamh Louise Marriott, Digital Editor
In a rodent model of islet transplantation, ARA 290 markedly reduced transplantation-induced inflammation, resulting in a marked increase in islet survival...
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the American Society for Microbiology (ASM) have just closed a joint conference in Vienna, which aimed to help researchers accelerate the development of new antimicrobials and to shed light on the challenges associated with antimicrobial resistance.
16 March 2016 | By Steve Bates, BioIndustry Association (BIA) Chief Executive
Here, Steve Bates, Chief Executive of the BioIndustry Association (BIA), makes a case for the UK remaining in the EU from the perspective of the life sciences sector...
9 June 2015 | By Victoria White
AM‐Pharma has announced that the FDA and EMA have both granted orphan designation status to recAP for the treatment of hypophosphatasia...
25 July 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig®...
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
Over the past few years, the landscape of medicines development has shifted. We have seen a decline in the research and development productivity of the pharmaceutical industry. Innovator drug developers have been confronted with the current pressure on healthcare budgets, as well as a wave of patent expiries for blockbuster…
